Definium Therapeutics, Inc.

There's a real but measured seasonal tilt here, toward February — the firmest corner of the calendar, higher in 6 of 9 Februaries.

A typical February brings +4.0%, a shade under the +6.0% average. That reliability comes with real swings, mind — even February ranges by 23.2% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — February has outpaced the S&P 500 by +6.3 points on average. It is the more striking for the company it keeps — February is a losing month for most of the market, where barely 49% of names gain ground.

It doesn't stand entirely alone — November and December have leaned firm as well, if less emphatically. At the other end of the calendar, March is the year's low point, though even there the stock has stayed positive on average (+1.5%), a sign every month leans up, and the edge isn't year-round — the stock has trailed the S&P 500 in June, July, and May. Its roughest month on record was a −83.3% July in 2019 — a reminder of how hard even a seasonal name can fall.

If anything it has sharpened recently — the last five Februaries run ahead of the earlier years.

Treat it as a tendency rather than a rule — seasonality describes the past, not a promise. With returns that swing hard year to year, the signal is best held loosely.